The effect of Dapagliflozin on coronary microcirculation in patients with heart failure with preserved ejection fraction: Controlled experiments before and after
In patients with heart failure with preserved ejection fraction, a 6-month Dapagliflozin regimen significantly improved clinical outcomes, exercise capacity, and quality of life without inducing detectable changes in resting coronary microcirculatory function, suggesting its benefits are mediated through systemic rather than direct local microvascular mechanisms.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Heart failure is a condition where the heart struggles to pump enough blood to meet the body's needs. For decades, doctors have focused heavily on hearts that are too weak to squeeze with enough force. However, a different and increasingly common type of heart failure exists where the heart squeezes normally but has become stiff and resistant to filling with blood. This is known as heart failure with preserved ejection fraction. In these patients, the problem often lies not in the main pumping chambers, but in the tiny, hair-thin blood vessels that feed the heart muscle itself. When these microscopic vessels fail to relax and open up properly, the heart muscle becomes starved of oxygen, leading to stiffness and symptoms like breathlessness and fatigue. For years, researchers have wondered if a specific class of drugs, originally designed to help manage blood sugar, could directly fix these clogged or stiff tiny vessels and restore the heart's ability to fill properly.
A team of researchers at the Foshan Second People's Hospital in China set out to answer this question with a focused study involving twenty-nine patients suffering from this specific type of heart failure. They wanted to see if giving these patients a drug called Dapagliflozin for six months would physically improve the flow of blood through the heart's microscopic network. To get a clear picture, the researchers used a powerful type of MRI scan, a technique that uses magnetic fields and radio waves to create detailed images of the heart without any needles or radiation. This imaging allowed them to measure exactly how fast blood arrived at different parts of the heart muscle, how quickly it peaked, and how well it flowed through the tissue. They also tracked standard health markers, such as the size of the heart chambers, the amount of protein leaking into the urine, and how far the patients could walk in six minutes.
The results of the six-month treatment revealed a surprising disconnect between what the patients felt and what the heart's tiny vessels appeared to do. The patients reported feeling significantly better. They were able to walk farther during their six-minute walk tests, and their scores on quality-of-life questionnaires improved markedly. Blood tests showed a clear drop in the levels of a stress hormone called BNP, which rises when the heart is under strain, and a significant reduction in protein in the urine, indicating that the kidneys were under less stress. These were clear, measurable signs that the treatment was helping the body function better.
However, when the researchers looked at the detailed MRI images of the heart's blood flow, the story was different. The scans showed no significant change in how blood moved through the tiny vessels. The speed at which blood arrived, the time it took to reach its peak, and the overall flow rate remained largely the same as they were before the treatment started. The size of the heart's chambers and the stiffness of the heart muscle also did not change in a statistically meaningful way. The drug did not appear to physically unclog or widen the microscopic blood vessels in the heart, nor did it reverse the structural stiffness of the heart muscle itself during this six-month period.
This finding suggests that the benefits patients experienced were not caused by a direct repair of the heart's tiny blood vessels. Instead, the researchers propose that the drug likely worked through broader, systemic effects on the body. By helping the kidneys remove excess fluid and salt, the drug may have reduced the overall volume of blood the heart had to pump, effectively taking the load off the heart. It may have also improved how the body uses energy or reduced inflammation throughout the system. These body-wide changes likely made the heart's job easier, allowing patients to feel stronger and walk farther, even though the microscopic plumbing inside the heart muscle remained unchanged.
The study highlights a complex reality in treating this form of heart failure. While the drug provided real, tangible relief for the patients, it did not act as a direct fix for the specific vascular defect that was suspected to be the root cause. The researchers noted that their study was relatively small and focused on patients at rest, meaning it is possible that the drug could improve blood flow only when the heart is working harder, a scenario they did not test. Nevertheless, the work provides a clear map of what this treatment can and cannot do. It confirms that patients can feel much better and have better organ function without seeing a direct reversal of the heart's microscopic blood flow issues, suggesting that the path to healing in these cases may lie in helping the whole body rather than just fixing the heart's tiny vessels.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.